New cancer drug AOH1996 enters first human tests
NCT ID NCT05227326
First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new drug called AOH1996 in 92 adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The drug works by blocking a protein that cancer cells need to grow. The main goals are to find the safest dose and see what side effects occur, while also checking if tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AOH1996 (a drug that blocks a protein cancer cells need to grow)
- What this could lead to
- If it works, this could point toward a new treatment option for people with solid tumors that haven't responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial focused on safety and dosing, so it's unknown if AOH1996 will effectively shrink tumors. Side effects are possible and being closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Email: •••••@•••••
-
City of Hope at Long Beach Elm
RECRUITINGLong Beach, California, 90813, United States
-
Honor Health Research and Innovation Institute
NOT_YET_RECRUITINGScottsdale, Arizona, 85258, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer